Cencora (COR) Stock Forecast & Price Target

$330.86 -6.36 (-1.89%)

As of 01:36 PM Eastern

Compare

Cencora - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
3

Buy
13

Based on 16 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, and 13 have given a buy rating for COR.

Consensus Price Target

$370.85
12.08% Upside

According to the 16 analysts' twelve-month price targets for Cencora, the average price target is $370.85. The highest price target for COR is $440.00, while the lowest price target for COR is $285.00. The average price target represents a forecasted upside of 12.08% from the current price of $330.86.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COR Analyst Ratings Over Time

Type	Current Forecast 9/4/25 to 9/4/26	1 Month Ago 8/5/25 to 8/5/26	3 Months Ago 6/6/25 to 6/6/26	1 Year Ago 9/4/24 to 9/4/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)	9 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$370.85	$367.75	$380.25	$311.25
Forecasted Upside	12.08% Upside	15.76% Upside	38.30% Upside	6.31% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Healthcare Companies	Broader Market
Consensus Rating Score	2.81	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	11.08% Upside	948.06% Upside	13.85% Upside
News Sentiment Rating	Positive News See Recent COR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/19/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Initiated Coverage	Sector Perform	$330.00	+4.31%
8/11/2026	Wells Fargo & Company 3 of 5 stars	Stephen Baxter 4 of 5 stars	Boost Target	Overweight	$331.00 ➝ $395.00	+21.85%
8/7/2026	Morgan Stanley 3 of 5 stars	Erin Wright 4 of 5 stars	Boost Target	Overweight	$342.00 ➝ $346.00	+7.00%
8/7/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$382.00 ➝ $390.00	+20.86%
8/6/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rodgers Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$370.00	+18.08%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$412.00 ➝ $430.00	+35.25%
8/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$350.00	+10.18%
8/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Funk Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$280.00 ➝ $285.00	-0.80%
The Supreme Court just made this coin more relevant (Ad) I’ve spent years searching for overlooked cryptos before the crowd catches on. Here are a few of our past recommendations: KDA: 17,556%, PRE: 3,900%, OCEAN: 2,650%, ALBT: 1,933% I’m always searching for the same thing: A strong crypto opportunity most investors haven’t discovered yet. And right now, my attention is on one coin trading for under $1. My research team and I have spent years studying emerging blockchain projects before they become widely followed. Previous recommendations have included OCEAN, KDA and PRE, along with other projects that produced substantial gains during their strongest runs. But we believe this project combines several traits that are rarely found in one opportunity. Get the name and full “Freedom Coin” research here.
6/10/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Glen Santangelo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$425.00 ➝ $350.00	+25.38%
4/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform
3/17/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
1/22/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Tanquilut Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Buy
11/10/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$350.00 ➝ $400.00	+10.23%
11/6/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Valiquette Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$340.00 ➝ $380.00	+7.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:36 PM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 3, 2026. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

Cencora, Inc. recently raised its fiscal 2026 earnings per share (EPS) outlook, signaling that its specialty businesses are driving stronger profit growth despite broader market pressures. This upward revision suggests management has confidence in the company's ability to maintain profitability, which is a positive indicator for shareholders looking for consistent earnings momentum.
The company demonstrated strong financial performance in its most recent quarterly report, beating analyst consensus estimates for both earnings per share and revenue. With revenue up 5.1% year-over-year, Cencora, Inc. is showing solid top-line growth, which indicates that its core distribution and healthcare services are resonating with customers and contributing to a robust bottom line.
Wall Street analysts maintain a "Moderate Buy" consensus rating for the stock, with an average price target of $374.25. This target price represents a potential upside of approximately 11% from the current stock price of $336.77, suggesting that professional investors believe the stock is currently undervalued relative to its future earnings potential.
Cencora, Inc. has a low beta of 0.57, meaning its stock price tends to be less volatile than the overall market. For investors seeking stability, this lower sensitivity to market swings can provide a defensive characteristic, potentially reducing portfolio risk during periods of broader economic uncertainty.
The company has a strong dividend yield of 0.74% and a low payout ratio of 17.83%, indicating that it retains the majority of its earnings for reinvestment or debt reduction. This conservative approach to dividends provides a safety margin for the company's financial health while still offering a steady income stream to shareholders.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

Cencora, Inc. carries a high debt-to-equity ratio of 3.53, which indicates a significant level of leverage relative to its equity base. While the company has a current ratio of 0.93, suggesting it may face short-term liquidity challenges, the high debt load can increase financial risk and interest expenses, potentially pressuring future earnings if interest rates remain elevated or if revenue growth slows.
Recent insider trading activity shows a trend of selling, with several executives, including the CEO and EVPs, reducing their positions in the past year. For example, the CEO sold shares in January 2026, and an EVP sold a significant portion of their holdings in August 2026. While insider sales can be due to personal financial needs, a pattern of selling may signal a lack of confidence in the stock's near-term upside from those closest to the company's operations.
The stock price of $336.77 is below its 52-week high of $377.54, indicating that the stock has experienced a pullback from its peak. This decline suggests that investors may be reassessing the company's valuation or facing concerns about its growth trajectory, which could lead to further volatility or downward pressure on the share price in the near term.
Cencora, Inc. operates in a highly competitive healthcare distribution sector, where margins are often thin and subject to regulatory and pricing pressures. The company's net margin of 0.79% is relatively low, meaning that even small changes in costs or pricing can significantly impact profitability. This sensitivity to operational efficiency and market conditions poses a risk to consistent earnings growth.
While the company has a strong institutional ownership of 97.52%, this also means that a large portion of the stock is held by large funds that may make significant trades based on macroeconomic factors or portfolio rebalancing. Such large-scale selling by institutional investors can create downward pressure on the stock price, making it more volatile and potentially harder for individual investors to predict short-term price movements.

COR Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $370.85, with a high forecast of $440.00 and a low forecast of $285.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" COR shares.

According to analysts, Cencora's stock has a predicted upside of 12.08% based on their 12-month stock forecasts.

Over the previous 90 days, Cencora's stock had 1 upgrade and 1 downgrade by analysts.

Cencora has been rated by research analysts at Bank of America, Barclays, Citigroup, Evercore, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Cencora more than other "healthcare" companies. The consensus rating for Cencora is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how COR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Cencora Recommendations

MarketBeat monitors more than a dozen sources for Cencora analyst ratings, with the most recent rating issued on 8/19/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Stock Forecast & Price Target

Cencora - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

COR Analyst Ratings Over Time

COR Analyst Recommendations By Month

COR Price Targets by Month

Cencora Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Cencora Stock? COR Pros and Cons Explained

Cencora
Bull Case

Cencora
Bear Case

COR Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Cencora Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cencora (COR) Stock Forecast & Price Target

Cencora - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

COR Analyst Ratings Over Time

COR Analyst Recommendations By Month

COR Price Targets by Month

Cencora Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Cencora Stock? COR Pros and Cons Explained

Cencora Bull Case

Cencora Bear Case

COR Forecast - Frequently Asked Questions

What is Cencora's forecast for 2026?

Should I buy or sell Cencora stock right now?

Does Cencora's stock price have much upside?

Has Cencora been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Cencora?

Do Wall Street analysts like Cencora more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Cencora Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Cencora
Bull Case

Cencora
Bear Case